News
Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
It's been a really good year for Exelixis (NASDAQ: EXEL). The biotech's share price has jumped more than 60% so far in 2017, thanks to continued momentum for its kidney cancer drug Cabometyx. But....
3 Biotech Stocks That Soared This Week: Are They Buys?
There's nothing like good results from a clinical study to light a fire beneath a biotech stock. That's what has happened with several biotechs over the last few days.Madrigal Pharmaceuticals....
Here's Why Spectrum Pharmaceuticals, Inc. Is Surging Today
Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a biopharmaceutical company primarily focused on cancer and blood-based disorders, are rising in response to some surprising early stage....
This Marijuana Stock May Already Be Running Out of Chances to Succeed
In case you haven't noticed, the marijuana industry is growing by leaps and bounds. According to cannabis research firm ArcView, the legal weed industry in North America is estimated to grow by....
Why Intercept Pharmaceuticals Is Tumbling Today
Intercept Pharmaceuticals (NASDAQ: ICPT), a biotech focused on liver diseases, fell 21% as of 3:26 p.m. EDT Thursday. The fall is traceable to a safety announcement released by the FDA that warns....
Why Calgon Carbon, Kindred Healthcare, and Impax Laboratories Jumped Today
Thursday was a down day for the stock market, but major benchmarks managed to limit their losses to modest amounts of less than half a percent. Investors looked at a wide variety of different....
Why Nabriva Therapeutics Shares Are Falling Today
For the third day in a row Wednesday, shares of Nabriva Therapeutics (NASDAQ: NBRV), a clinical-stage biotech focused on antibiotics, were moving by double-digits. However, today's move is in the....
Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today
After reporting disappointing interim news from its phase 3 study of SPN-810 as a treatment for aggressive impulses in ADHD patients, shares in Supernus Pharmaceuticals (NASDAQ: SUPN) tumbled....
What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today?
Shares of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a small-cap biotech with a several irons in the fire, are on the rise today. Despite a lack of significant news, the stock tacked on a....
Why Nabriva Therapeutics PLC Is Skyrocketing
Investors in Nabriva Therapeutics (NASDAQ: NBRV) are having a wonderful start to the trading week. Shares of the clinical-stage biotech focused on antibiotics rose 36% as of 11:30 a.m. EDT on....
Is ImmunoGen Running Out of Steam, or Taking a Breather?
There's good news and bad news for ImmunoGen (NASDAQ: IMGN) shareholders. The good news is that the biotech stock is up more than 230% so far in 2017. The bad news? Shares have dropped nearly 20%....
Why Abeona Therapeutics Inc Stock Jumped Higher Today
Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned....
3 Biotech Stocks I'd Buy Right Now
It's been a banner year so far for biotech, but a handful of stocks have been travelling in the opposite direction of the iShares Nasdaq Biotechnology index. The industry-tracking index has risen....
Is Intrexon Corporation Stock Now a Bargain?
According to data from S&P Global Market Intelligence , Intrexon Corporation (NYSE: XON), a synthetic biology company, saw its shares dip by 7.72% last month. The company's shares struggled....
Why Shares of ImmunoGen, Inc. Sank Today
Shares of ImmunoGen (NASDAQ: IMGN) closed down 10.6% on Tuesday after the company disclosed that it exchanged some of its 4.5% convertible senior notes due in 2021 for newly issued shares.The....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 août 2017
Le 8 septembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Here's Why the Best Is Yet to Come for Cara Therapeutics, Inc.
By late June, Cara Therapeutics, Inc. (NASDAQ: CARA) stock had soared more than 175% year to date. Within a couple of weeks, however, many of those gains had been lost. Cara shares crashed after....
Why NewLink Genetics Is Soaring 37.5% Higher Today
After NewLink Genetics Corporation (NASDAQ: NLNK) updated data from its ongoing phase 2 trial of IDO inhibitor indoximod in advanced melanoma, shares in the immuno-oncology specialist shot higher....
Why Intra-Cellular Therapies Is Surging Today
Shares of Intra-Cellular Therapies (NASDAQ: ITCI), a clinical-stage pharma company focused on diseases of the central nervous system, jumped more than 17% as of 3:15 p.m. EDT on Thursday. The....
QUANTUM GENOMICS : Présentation de Quantum Genomics à la conférence Rodman et Renshaw 2017
Paris, le 7 septembre 2017
Quantum Genomics (Euronext Growth − FR0011648971 − ALQGC), société biopharmaceutique spécialisée dans le développement de nouvelles thérapies pour des besoins....
Quantum Genomics to Present at Rodman and Renshaw 19th Annual Global Investment Conference
Paris & New York, September 7, 2017
Quantum Genomics (Euronext Growth − FR001164897 − ALQGC; OTCQX: QNNTF), a biopharmaceutical company with the mission of developing new therapies for....
BOIRON : Résultats semestriels 2017
(Données ayant fait l'objet d'une revue limitée par les commissaires aux comptes)
Le Conseil d'Administration de BOIRON, réuni le 7 septembre 2017, a établi les comptes sociaux et les comptes....
BOIRON : 2017 half-year results
(Data have been the subject to a limited review by the statutory auditors)
The Board of Directors of BOIRON, at its meeting of September 7, 2017, made up the half-year statutory and....
Here's Why Cara Therapeutics Rose 9.6% in August
Cara Therapeutics (NASDAQ: CARA), a clinical-stage biotech focused on drugs that relieve pain, rose by nearly 10% during August, according to data from S&P Global Market Intelligence. The jump....
5 Key Things You Should Watch With Jazz Pharmaceuticals
It's been a great year for Jazz Pharmaceuticals (NASDAQ: JAZZ) shareholders so far. The biotech stock is up more than 35% year to date. However, most of those gains were made in the first....